Valneva Reports Positive 12-Month Antibody Persistence Data For Chikungunya Vaccine Candidate

Reuters (12/5, Hummel) reports, “Vaccines company Valneva on Monday reported positive 12-month antibody persistence data for its single-shot Chikungunya vaccine candidate.” The company “said in a statement it was currently on track to complete its submiss...